What's the Problem?
Nanomedicines (NMDs) are nano-scale vehicles that contain drugs inside. They protect these drugs from getting destroyed inside the body, allowing them to act selectively on diseased cells and avoiding secondary side effects on healthy cells. Such innovations improve patient’s life quality by reducing their treatments’ heavy side effects and by allowing to increase the dose amount, achieving more effective therapies. However, after 40 years of intense research in NMDs, only 50 products worldwide have reached patients. Their main obstacle is that they are complex systems and highly dependent on the manufacturing process. The traditional technology used to produce NMDs works in turbulent flows, with uncontrolled synthesis and with high consumption of reagents and time. This method is far from optimal for the pharmaceutical industry requirements due to its batch-to-batch variations, long and inefficient processes and difficulties both in scalability and optimization.